Intravesical chemo-immunotherapy in non muscle invasive bladder cancer

D. Leopardo, S.C. Cecere, M. Di Napoli, C. Cavaliere, C. Pisano, S. Striano, L. Marra, L. Menna, L. Claudio, S. Perdonà, S. Setola, M. Berretta, R. Franco, R. Tambaro, S. Pignata, G. Facchini

Uro-Gynecologic Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale”, IRCCS, Napoli, Italia. s.pignata@istitutotumori.na.it

---

• Oncology

Non-Muscle-Invasive-Bladder-Cancer represents 75-85% of the new bladder cancer cases per year. Trans-uretral vesical resection is the milestone for diagnosis and therapy. After primary treatment, recurrence is frequent depending on the presence of several established risk factors: multiplicity, T dimension, prior recurrence. In some patients disease progress to an advanced stage. Adjuvant chemo-immunotherapy has been widely used depending on the risk category assigned on the basis of the risk factors for recurrence. In low risk categories a one shot treatment with chemotherapy is considered the standard treatment without any maintenance therapy. In intermediate risk patients, adjuvant induction therapy and maintenance chemotherapy or immunotherapy for at least one year is recommended. In high risk patients adjuvant induction and maintenance immunotherapy until 3 years is considered the best strategy.

In this review data on the different drugs used in this setting will be discussed.

Free PDF Download